MaxCyte, Inc. (NASDAQ:MXCT - Get Free Report) Director John Joseph Johnston sold 3,000 shares of the stock in a transaction that occurred on Monday, January 27th. The shares were sold at an average price of $4.64, for a total transaction of $13,920.00. Following the sale, the director now directly owns 141,950 shares of the company's stock, valued at $658,648. The trade was a 2.07 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
John Joseph Johnston also recently made the following trade(s):
- On Thursday, December 26th, John Joseph Johnston sold 3,000 shares of MaxCyte stock. The stock was sold at an average price of $4.01, for a total value of $12,030.00.
MaxCyte Stock Performance
MXCT stock traded down $0.04 on Wednesday, hitting $4.65. 426,831 shares of the company's stock were exchanged, compared to its average volume of 685,661. The firm has a 50 day moving average price of $4.20 and a two-hundred day moving average price of $4.08. MaxCyte, Inc. has a 12-month low of $3.16 and a 12-month high of $5.29. The stock has a market cap of $491.02 million, a P/E ratio of -13.66 and a beta of 1.29.
MaxCyte (NASDAQ:MXCT - Get Free Report) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.02. The firm had revenue of $8.16 million for the quarter, compared to the consensus estimate of $7.50 million. MaxCyte had a negative net margin of 78.36% and a negative return on equity of 16.00%. During the same quarter in the prior year, the company posted ($0.11) earnings per share. Sell-side analysts expect that MaxCyte, Inc. will post -0.42 earnings per share for the current fiscal year.
Institutional Investors Weigh In On MaxCyte
Institutional investors and hedge funds have recently modified their holdings of the company. Marshall Wace LLP purchased a new position in MaxCyte during the 2nd quarter worth approximately $1,959,000. ArrowMark Colorado Holdings LLC raised its holdings in shares of MaxCyte by 13.8% during the third quarter. ArrowMark Colorado Holdings LLC now owns 1,394,947 shares of the company's stock worth $5,426,000 after purchasing an additional 169,250 shares during the last quarter. Mudita Advisors LLP lifted its position in MaxCyte by 5.6% during the third quarter. Mudita Advisors LLP now owns 3,153,441 shares of the company's stock valued at $12,267,000 after purchasing an additional 167,101 shares during the period. Gagnon Securities LLC boosted its holdings in MaxCyte by 234.1% in the fourth quarter. Gagnon Securities LLC now owns 197,326 shares of the company's stock valued at $821,000 after purchasing an additional 138,257 shares during the last quarter. Finally, Barclays PLC grew its position in MaxCyte by 329.3% during the 3rd quarter. Barclays PLC now owns 165,765 shares of the company's stock worth $645,000 after purchasing an additional 127,156 shares during the period. Institutional investors and hedge funds own 68.81% of the company's stock.
About MaxCyte
(
Get Free Report)
MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider MaxCyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MaxCyte wasn't on the list.
While MaxCyte currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
